PhillipCapital has maintained its “buy” rating and target price of 26 cents on ClearBridge Health (CBH) on the back of a stronger 2H20 for the company. 

The Phillip Research Team said 1H20 revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) were within expectations with revenue coming in at $21.4 million and EBITDA at a positive $3.6 million. Operating cashflow also saw a reversal from negative$3.6million in 1H19 to $4.5 million in 1H20. 

They add CBH continues to expand and leverage its network of medical centres throughout ASEAN. The stronger operating cash-flow and balance sheet will allow CBH to further grow via acquisition and expand their Indonesian operations faster where the capital expenditure and working capital requirements are much higher.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook